A Pilot Study of Pembrolizumab Monotherapy or Pembrolizumab Based Combination Therapy in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma
Phase of Trial: Phase 0
Latest Information Update: 16 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Ramucirumab
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 12 Feb 2018 Planned End Date changed from 1 Mar 2022 to 1 Feb 2022.
- 12 Feb 2018 Planned primary completion date changed from 1 Mar 2022 to 1 Feb 2022.
- 12 Feb 2018 Status changed from not yet recruiting to recruiting.